Biotech earnings season continues with Horizon Pharma PLC (NASDAQ:HZNP) reporting fourth-quarter results on Monday, while Merrimack Pharmaceuticals Inc (NASDAQ:MACK) reported earnings yesterday after closing. Let’s take a look and see what analysts have to say about HZNP and MACK.

Horizon Pharma PLC

In a research report published Friday, Mizuho analyst Irina Rivkind Koffler reiterated a Buy rating on shares of Horizon Pharma, as the company is heading into Monday’s print.

Koffler noted, “We expect another strong quarter for HZNP. We model revs of $242.7M and $0.65 EPS relative to $240.9M and $0.62 consensus. We have also updated our model for guidance issued on Jan 12. We see potential upside to prior 2016 revenue guidance of $1,025-1,050M, and $505-520M in adjusted EBITDA from the recent “innovative drug” status designation of Ravicti in Canada. There are approximately 100 UCD patients in Canada and we note that most of them are already known to the company since they participated in a prior Ravicti trial.”

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Irina Rivkind Koffler has a yearly average return of 32.7% and a 59% success rate. Koffler has a 1.3% average return when recommending HZNP, and is ranked #6 out of 3675 analysts.

Merrimack Pharmaceuticals Inc

Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Merrimack, with a price target of $16, after the company reported its fourth-quarter results yesterday evening. The company outlined its ambitious commercial strategy and provided investors with an update on its clinical progress.

Aschoff commented, “Merrimack believes that Onivyde is on track to become standard of care in post-gemcitabine pancreatic cancer. The supply chain, manufacturing, distribution, field team, and related logistics for Onivyde are in place. The ESMO treatment guidelines already include Onivyde and approval in the EU is expected in 2016.”

Furthermore, “Merrimack started the Phase 2 trial of Onivyde plus 5-FU and LV with or without oxaliplatin in previously untreated front-line metastatic pancreatic cancer, and we expect results in 1H17. At the recent ASCO GI meeting, Merrimack presented data from the Phase 3 NAPOLI-1 trial that Onivyde in combination with 5-FU and LV achieved a 63% improvement in 12-month OS compared to 5-FU and LV alone. Merrimack ended 4Q15 with $185.6M in cash and equivalents, which should be enough to carry the company through to profitability in 2018, by our estimate.”

According to, analyst Jonathan Aschoff has a yearly average return of -14.0% and a 29.3% success rate. Aschoff has a -15.5% average return when recommending MACK, and is ranked #3651 out of 3675 analysts.


Out of the 5 analysts polled by TipRanks, 4 rate Merrimack stock a Buy, while 1 rates the stock a Hold. With a return potential of 169%, the stock’s consensus target price stands at $15.